Margins matter. The more Exactech (NAS: EXAC) keeps of each buck it earns in revenue, the more money it has to invest in growth, fund new strategic plans, or (gasp!) distribute to shareholders.

GAINESVILLE, Fla., Feb. 18, 2025 /PRNewswire/ — Exactech, a global leader in medical technology, presented 15 new studies describing new research and advancements in total joint arthroplasty and ...

Exactech is a medical device company that manufactures implantable joint replacements. It is also a company that has faced numerous lawsuits related to its products in recent years. In many cases, ...

Over the past couple of decades, hundreds of thousands of patients in the United States have received defective medical implants manufactured by Exactech. While the U.S. Food and Drug Administration ...

There's no foolproof way to know the future for Exactech (NAS: EXAC) or any other company. However, certain clues may help you see potential stumbles before they happen -- and before your stock ...

Exactech, an orthopedic implants maker, received a warning letter related to its handling of packaging problems that could cause its implants to degrade faster. The Food and Drug Administration sent ...

Producer of bone and joint restoration products, Exactech Inc. (EXAC) recently announced that it has acquired BlueOrtho SAS – a firm engaged in computer-assisted surgical technology development and ...

Margins matter. The more Exactech (Nasdaq: EXAC) keeps of each buck it earns in revenue, the more money it has to invest in growth, fund new strategic plans, or (gasp!) distribute to shareholders.

Christy Bieber has a JD from UCLA School of Law and began her career as a college instructor and textbook author. She has been writing full time for over a decade with a focus on making financial and ...

Exactech Inc. (Nasdaq: EXAC) has agreed to acquire Altiva Corp., a Charlotte, N.C.-based maker of spinal implant devices and related products. The deal represents Exactech's decision to exercise a ...

It takes money to make money. Most investors know that, but with business media so focused on the "how much," very few investors bother to ask, "How fast?" When judging a company's prospects, how ...

Medical devicemaker Exactech agreed to pay $8 million to settle allegations that it knowingly marketed and sold defective components within its line of Optetrak total knee systems, which have been ...